Preparing the Path for Biotechnology and Nanotechnology: Perspectives From the U.S. Department of Commerce Technology Administration
Bond, Phillip J.
Journal of Biolaw and Business 2004; 7(2): 3-7
Showing items related by title, author, creator and subject.
Mutual Recognition Agreement: Food and Drug Administration's Progress in Assessing Equivalency of European Union Pharmaceutical Inspection Programs Letter From William J. Scanlon, Director, Health Financing and Public Health Issues to Rep. Thomas Bliley, Jr. and Rep. John D. Dingell on the U.S. Congress, House, Committee on Commerce and Rep. Fred Upton and Rep. Ron Klink on the U.S. Congress, House, Committee on Commerce, Subcommittee on Oversight and Investigations Scanlon, William J. (United States. General Accounting Office [GAO]. Health, Education and Human Services Division, 1999-02-26)
Conspiracy of Silence: How the FDA Allows Drug Companies to Abuse the Accelerated Approval Process. Staff Summary of Responses by the Food and Drug Administration and the Securities and Exchange Commission to Correspondence From Rep. Edward J. Markey (D-MA), Senior Member, Energy and Commerce Committee, U.S. House of Representatives Unknown author (United States. House of Representatives. Energy and Commerce Committee, 2005-06)